Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol

Kidney International

Volumn 55, Issue 6, 1999, Pages 2169-2177

  Ghazali, Abderhaman ^a,b,c,d   Fardellone, Patrice ^a,b,c,d   Pruna, André ^a,b,c,d   Atik, Ahcene ^a,b,c,d   Achard, Jean Michel ^a,b,c,d   Oprisiu, Roxana ^a,b,c,d   Brazier, Michel ^a,b,c,d   Remond, Alex ^a,b,c,d   Morinière, Philippe ^a,b,c,d   Garabedian, Michèle ^a,b,c,d   Eastwood, John ^a,b,c,d   Fournier, Albert ^a,b,c,d  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b BADJI MOKHTAR UNIVERSITY   (Algeria)

^c CNRS   (France)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Hemodialysis; Hypercalcemia; Metabolites; Parathyroid hormone; Vitamin D

Indexed keywords

CALCITRIOL;

ADULT; ARTICLE; CALCIUM INTAKE; CHRONIC KIDNEY FAILURE; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN INTAKE;

EID: 0033031374     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00480.x     Document Type: Article

References (41)

1. 1. Reichel H, Drüeke T, Ritz E: The patient with uremia skeletal disorders, in Oxford Textbook of Clinical Nephrology (vol 3), Oxford, Oxford University Press, 1997, 1954-1981
2. 2. Cunningham J, Makin H: How important is vitamin D deficiency in uremia? Nephrol Dial Transplant 12:16-18, 1997
3. 3. Lucas PA, Woodhead JS, Brown RC: Vitamin D3 metabolites in chronic renal failure and transplantation. Nephrol Dial Transplant 3:70-76, 1988
4. 4. Halloran BI, Schaeffer P, Lieschitz M, Levens M, Goldsmith RS: Plasma vitamin D. J Clin Endocrinol Metab 59:1053-1069,1984
5. 5. Dusso A, Brown A, Slatopolsky E: Extrarenal production of calcitriol. Semin Nephrol 14:144-145, 1994
6. 6. Fournier A, Bordier PH, Gueris J, Sebert JL, Marie P, Ferriere C, Bedrossian J, Deluca HF: Comparison of 1-alphahydroxycholecalciferol and 25 hydroxy-cholecalciferol in the treatment of renal osteodystrophy: Greater effect of 25 hydroxy-cholecalciferol on hone mineralization. Kidney Int 15:196-204, 1979
7. 7. Van Der Wielen RP, Lowik MR, Van Den Berg H, De Groot L, Haller J, Mereiras W, Van Staweren WA: Serum vitamin D concentrations in elderly in Europe. Lancet 346:207-210, 1995
8. 8. Zehgoud F, Vervel C, Guillozo H, Wabrant-Debray O, Boutignon H, Garabedian M: Subclinical vitamin D deficiency in neonates: Definition and response to vitamin D supplements. Am J Clin Nutr 65:771-778, 1997
9. 9. Docio S, Riancho JA, Perez A, Olmos JH, Amado JA, Gonzales-Macias J: Seasonal deficiency of vitamin D in children: A potential target for osteoporosis preventing strategies. J Bone Miner Res 13:544-548, 1998
10. 10. Thomas MK, Lloyd Jones DM, Thadam AJ, Shaw AC, Finkelstein R: Hypovitaminosis D in medical inpatients. N Engl J Med 338:777-783, 1998
11. 11. Dawson-Hughes B, Harris S, Krall EA, Dallal GE, Falconer G, Green CL: Rates of bone loss in post menopausal women randomly assigned to one of two dosages of vitamin D. Am J Nutr 61:1140-1145, 1995
12. 12. Brown RC, Aston JP, Weeks I, Woodhead JS: Circulating intact parathyroid hormone measured by a two site immunochemiluminometric assay. J Clin Endocrinol Metab 65:407-414, 1987
13. 13. Allain P, Mauras Y: Determination of aluminium in blood, urine and water by inductively coupled plasma emission spectrometry. Anal Chem 51:2089-2095, 1979
14. 14. Preece MA, O'Riordan JLH, Lawson DEM, Kodicek E: A competitive protein-binding assay for 25-hydroxycholecalciferol and 25-hydroxyergocalciferol in serum. Clin Chem Acta 54:235-242, 1974
15. 15. Shepard RM, Horst RL, Mamstra AJ, De Luca HF: Determination of vitamin D and its metabolites in plasma from normal and anephric man. Biochem J 182:55-69, 1979
16. 16. Wang M, Hercz G, Sherrard DJ, Segre GV, Pei Y: Relationship between intact PTH 1-84 parathyroid hormone and bone histomorphometry parameters in dialysis patients without aluminium toxicity. Am J Kidney Dis 26:836-844, 1995
17. 17. Hutchinson AJ, Whitehouse RW, Boulton HF: Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end stage renal disease. Kidney Int 44:1071-1077, 1993
18. 18. Pazianas M, Phillips ME, MacRae KD, Eastwood JB: Identification of risk factors for radiographic hyperparathyroidism in 422 patients with end-stage renal disease: Development of a clinical predictive index. Nephrol Dial Transplant 7:1098-1105, 1992
19. 19. Parfttt AM, Massry SG, Winfield AC, De Palma JR, Gordon A: Disordered calcium and phosphorus metabolism during maintenance hemodialysis: Correlation of clinical, roentgenographic and biochemical changes. Am J Med 51:319-323, 1971
20. 20. Pei T, Hercz G, Greenwood C, Sherrard D, Segre D, Manuel A, Saiphoo C, Fenton S: Non invasive prediction of aluminum bone disease in hemo-and peritoneal dialysis patients. Kidney Int 41:1374-1382, 1992
21. 21. Bayard F, Bey P, Ton That M, Louvet J: Plasma 25OH cholecalciferol in chronic renal failure. Eur J Clin Invest 3:447-450, 1973
22. 22. Clements MR, Davis M, Fraser DR, Lumb A, Mawer EB, Adams PH: Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism. Clin Sci 73:659-664, 1987
23. 23. Mawer EB, Backhouse J, Hill LF, Lumb GA, Stanbery SW: Vitamin D metabolism and parathyroid function in man. Clin Sci Mol Wed 48:349-365, 1975
24. 24. Clements MR, Johnson L, Fraser DR: A new mechanism for induced vitamin D deficiency in calcium deprivation. Nature 325:62-65, 1987
25. 3 administration in the rat, reduces the serum concentration of 25OH vitamin D by increasing metabolic clearance rate. J Clin Invest 78:622-628, 1986
26. 2 vitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol 37:17-27, 1992
27. 27. Silver J, Moallern E, Kilav R, Epstein L, Sela A, Naveh Many T: New insight in the regulation of parathyroid hormone synthesis and secretion in chronic renal failure. Nephrol Dial Transplant 11(Suppl 3):2-5, 1996
28. 28. Boonen S, Vanderschuren D, Cheng XG, Verbeke G, Dequeker J, Bouillon R: Age related (type II) femoral neck osteoporosis in men: Biochemical evidence of both hypovitaminosis D and androgeny deficiency induced bone resorption. J Bone Miner Res 12:2119-2126, 1997
29. 29. Qaw F, Calverley MJ, Schroeder NJ, Trafford DJ, Makin HL, Jones G: In vivo metabolism of the vitamin D analog, dihydrotachysterol: Evidence for formation of 1 alpha, 25-and 1 beta, 25-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem 268:282-292, 1993
30. 30. Heaney RP, Barger-Lux MJ, Dowell S, Chen TC, Holick MF: Calcium absorption effects of vitamin D and its major metabolites. J Clin Endocrinol Metab 82:4111-4116, 1997
31. 2 vitamin D in vitamin D toxicity. Ann Int Med 122:511-513, 1995
32. 3 therapy for bone disease in dialysis patients. Bone 13:369-377, 1992
33. 3 suppresses the serum PTH levels of dialysis patients. Nephron 58:283-287, 1991
34. 2 vitamin D supplementation corrects hyperparathyroidism and improves skeletal abnormalities in X linked hypophosphatemic rickets: A clinical research center study. J Clin Endocrinol Metab 81:2381-2388, 1996
35. 35. Eastwood JB, Harris E, Stamp TCB, De Wardener HE: Vitamin-D deficiency in the osteomalacia of chronic renal failure. Lancet 2:1209-1211, 1976
36. 36. Memmos DE, Eastwood JB, Harris E, O'Grady AJ, De Wardener HE: Response of uremic osteoid to vitamin D. Kidney Int 21(Suppl 11):S50-S54, 1982
37. 37. Bordier PJ, Tun Chot S, Eastwood JB, Fournier AE, De Wardener HE: Lack of histological evidence of vitamin D abnormality in the bones of anephric patients. Clin Sci 44:33-41, 1973
38. 38. Eastwood JB, Bordier PJ, Clarkson EM, Tun Chot S, De Wakdener HE: The contrasting effect on bone histology of vitamin D and of calcium carbonate in the osteomalacia of chronic renal failure. Clin Sci Mol Med 47:23-42, 1974
39. 3. Kidney Int 33(Suppl 24):S178-S179, 1988
40. 40. Compston JE: Vitamin D deficiency: Time for action evidence supports routine supplementation for elderly people and others at risk. BMJ 317:1466-1467, 1998
41. 41. Goldberg DI, Dillon M, Slatopolsky EA, Garrett B, Gray JR, Marburry T, Weinberg M, Wombolt D, Burke SK: Effect of Renagel® a non absorbed, calcium and aluminum free phosphate binder on serum phosphorus, calcium and intact PTH in end stage renal disease patients. Nephrol Dial Transplant 13:2303-2310, 1998